Professor | Li Hu | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Li Hu

Contact Information

huli@njmu.edu.cn

Language ability

Chinese, English

Province

Jiangsu

University/Lab Affiliation and Title	Nanjing Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2021-2023 Postdoctoral Research: Nanjing Medical University, Suzhou College 2021 PhD: Nanjing Medical University, School of Basic Medicine 2016 Bachelor's: Nanjing Medical University, Forensic Medicine Hosted National Natural Science Foundation - Youth Fund Project Selected for Jiangsu Province Outstanding Postdoctoral Program
Work Experience	2023-present - Nanjing Medical University, School of Basic Medicine, Associate Professor 2021-2023 - Nanjing Medical University, Postdoctoral Researcher
Awards	2022: Approved as Jiangsu Province Outstanding Postdoctoral

University/Lab Affiliation and Title

Nanjing Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

Work Experience

2023-present - Nanjing Medical University, School of Basic Medicine, Associate Professor
2021-2023 - Nanjing Medical University, Postdoctoral Researcher

Awards

Areas of Focus	Basic and translational research on cardiovascular diseases
Publications	Ythdf2 promotes pulmonary hypertension by suppressing Hmox1-dependent anti-inflammatory and antioxidant function in alveolar macrophages., Li Hu, Yanfang Yu, Yueyao Shen, Huijie Huang, Donghai Lin, Kang Wang, Youjia Yu, Kai Li, Yue Cao, Qiang Wang, Xiaoxuan Sun, Zhibing Qiu, Dong Wei, Bin Shen, Jingyu Chen, David Fulton, Yong Ji, Jie Wang, Feng Chen, 2023 Mesenchymal Stem Cell-derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension., Li Hu, Jie Wang, Donghai Lin, Yueyao Shen, Huijie Huang, Yue Cao, Yan Li, Kai Li, Yanfang Yu, Youjia Yu, Chunyan Chu, Lianju Qin, Xiaojian Wang, Haifeng Zhang, David Fulton, Feng Chen, 2022 YTHDF1 Regulates Pulmonary Hypertension through Translational Control of MAGED1., Li Hu, Jie Wang, Huijie Huang, Yanfang Yu, Jingjing Ding, Youjia Yu, Kai Li, Dong Wei, Qing Ye, Fangzhu Wang, Bin Shen, Jingyu Chen, David J R Fulton, Feng Chen, 2021 CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy., Jie Wang, Li Hu, Huijie Huang, Yanfang Yu, Jingshen Wang, Youjia Yu, Kai Li, Yan Li, Tian Tian, Feng Chen, 2020

Areas of Focus

Basic and translational research on cardiovascular diseases

Publications

Ythdf2 promotes pulmonary hypertension by suppressing Hmox1-dependent anti-inflammatory and antioxidant function in alveolar macrophages., Li Hu, Yanfang Yu, Yueyao Shen, Huijie Huang, Donghai Lin, Kang Wang, Youjia Yu, Kai Li, Yue Cao, Qiang Wang, Xiaoxuan Sun, Zhibing Qiu, Dong Wei, Bin Shen, Jingyu Chen, David Fulton, Yong Ji, Jie Wang, Feng Chen, 2023
Mesenchymal Stem Cell-derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension., Li Hu, Jie Wang, Donghai Lin, Yueyao Shen, Huijie Huang, Yue Cao, Yan Li, Kai Li, Yanfang Yu, Youjia Yu, Chunyan Chu, Lianju Qin, Xiaojian Wang, Haifeng Zhang, David Fulton, Feng Chen, 2022
YTHDF1 Regulates Pulmonary Hypertension through Translational Control of MAGED1., Li Hu, Jie Wang, Huijie Huang, Yanfang Yu, Jingjing Ding, Youjia Yu, Kai Li, Dong Wei, Qing Ye, Fangzhu Wang, Bin Shen, Jingyu Chen, David J R Fulton, Feng Chen, 2021
CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy., Jie Wang, Li Hu, Huijie Huang, Yanfang Yu, Jingshen Wang, Youjia Yu, Kai Li, Yan Li, Tian Tian, Feng Chen, 2020

Cardiovascular Disease Research Translational Basic Mechanism Intervention Strategy Development Targeted

Er Dan Dong - Peking University

Kong Wei - Peking University

Xunde Xian - Peking University

View All

Personal Information